Venus Medtech (Hangzhou) Inc.
Status: Publicly traded
Direct answer
Venus Medtech (Hangzhou) Inc. is publicly traded on HKSE under the ticker 2500.HK.
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients...
Can you invest in Venus Medtech (Hangzhou) Inc.?
Yes. Venus Medtech (Hangzhou) Inc. is publicly traded on HKSE under the ticker 2500.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Venus Medtech (Hangzhou) Inc.
Detailed equity research is provided by MarketSnap.